Shanghai, China – May 7, 2026 – MicroPort® Endovastec™ announced that its Fishhawk™ Mechanical Thrombectomy Device (Fishhawk™) has received marketing approval from the National Medical Products Administration (NMPA) of China. First admitted to the NMPA Green Channel for Innovative Medical Devices in 2022, Fishhawk™ provides a vital new treatment option for the percutaneous endovascular removal of acute iliac and femoral Deep Venous Thrombosis (DVT).
DVT is characterized by abnormal clot formation within deep veins, most commonly in the lower limbs. If untreated, it can lead to severe complications, including pulmonary embolism or post-thrombotic syndrome. Percutaneous Mechanical Thrombectomy (PMT) is an emerging, minimally invasive approach for the treatment of high-burden acute DVT that offers rapid clot removal. Fishhawk™ is specifically engineered to address key clinical challenges in this setting. The system incorporates four key design features to deliver optimal performance in acute venous thrombectomy:
“MicroPort® Endovastec™ has established a peripheral venous intervention product portfolio covering stents, balloon dilatation catheters, vena cava filters, snare retrieval kits, and thrombectomy device with several additional innovative products progressing through development,” said Zhenyu Yuan, PhD, Advanced Vice President of R&D at MicroPort® Endovastec™.
“As the seventh innovative medical device approved for commercialization under the NMPA’s Green Channel for innovative medical devices, Fishhawk™’s approval strengthens MicroPort® Endovastec™’s integrated venous disease treatment portfolio and supports the clinical and commercial development of our broader product offering,” said Qing Zhu, PhD, President of MicroPort® Endovastec™.
MicroPort® Endovastec™ continues to focus on innovation across aortic, peripheral vascular, and tumor intervention therapies, with a commitment to advancing the treatment options for physicians and expanding access to advanced solutions for patients worldwide.
About MicroPort® Endovastec™
Founded in 2012, MicroPort®Endovastec™ (Shanghai MicroPort Endovascular MedTech Group Co., Ltd.; SSE: 688016), an associated company of MicroPort® (MicroPort Scientific Corporation, HKEX: 00853), is a global medical device company focusing on the research, development, manufacturing, and commercialization of aortic, peripheral vascular and tumor interventional devices.
MicroPort® Endovastec™'s product portfolio includes thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, peripheral vascular stents, drug-coated balloon dilatation catheters, balloon dilatation catheters, vena cava filters, snare retrieval kits, thrombectomy device, and tumor embolization microspheres. The company is committed to advancing emerging technologies in great vessel surgery and peripheral vascular medicine and to providing access to state-of-the-art solutions for patients worldwide.
More information is available at: www.endovastec.com/en
Regulatory disclaimer
The Fishhawk™ Mechanical Thrombectomy Device has received marketing approval from the NMPA in China. Regulatory status varies by country and region. Not all products or indications described in this release may be approved in all markets. Healthcare professionals should refer to applicable local regulatory requirements and instructions for use.
References
Data on file, MicroPort® Endovastec™. Clinical trial ongoing; results pending.